Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: CUBBY who wrote (1423)	8/8/1998 4:21:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 4140

Does anyone know the reason why SNRS got delisted from NASDAQ before? Thanks. Best of Luck, Where'd He Go?

To: CUBBY who wrote (1423)	8/10/1998 7:31:00 AM
From: CUBBY	Read Replies (3) \| Respond to of 4140

******NASDAQ***********Sunrise Technologies International,Inc. Approved for Nasdaq National Market System Trading August 10, 1998 07:00 AM FREMONT, Calif.--(BW HealthWire)--Aug. 10, 1998--Sunrise Technologies International, Inc. SNRS -- maker of the Sunrise LTK Non-Contact Holmium YAG Laser System, announced today that they anticipate trading on the national market system of NASDAQ on Thursday, August 13th, 1998 under the ticker symbol SNRS. According to C. Russell Trenary III, President and CEO, "We are very proud to be listed on the NASDAQ National Market System and we believe this will be a tremendous benefit to current and future shareholders. This culminates our efforts over the past two years in establishing credibility for our company and our technology." Mr. Trenary also stated, "The Sunrise LTK Laser System potentially benefits what may be the largest patient group in the history of ophthalmology for the correction of hyperopia, presbyopia, and inadequately treated excimer laser patients. It is also worth noting that some of the leading cataract and refractive surgeons and their family members have been treated with this technology during our clinical trials. Sunrise Technologies, utilizing a patented approach, has completed enrollment for their clinical trial for low to moderate hyperopia under the auspices of the U.S. Food and Drug Administration (FDA). The company plans to submit its premarket approval application (PMA) to the FDA in the fourth quarter of this year. Additionally, clinical trials are ongoing for the correction of presbyopia, moderate to high hyperopia, and inadequately treated excimer laser patients. The company will be submitting supplements to the original PMA application as these clinical results are tabulated. Founded in 1987 the Company produces and markets high technology products revolutionizing treatment methods in eye care. The Company develops Holmium laser-based systems which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. Its Sunrise LTK(tm) System(a) is a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in FDA clinical trials in the United States. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com.